Abstract:With the application of Mendelian randomization and co‐localization analysis methods, we found compelling indications for two proteins (LRP11 and ITIH1) and suggested indications for four proteins (PLCG1, ARHGAP25, CHGA, and MANBA), which might be promising targets for migraine treatment without obvious adverse consequences. Background Proteome‐wide Mendelian randomization studies have been increasingly utilized to identify potential drug targets for diseases. We aimed to identify potential therapeutic targets for migraine and its subtypes through the application of Mendelian randomization and co‐localization analysis methods. Methods We utilized cis‐protein quantitative trait loci data for 1378 plasma proteins available from two studies with 7213 individuals and 35,559 individuals, respectively. Summary data for migraine and its subtypes were obtained from a genetic study involving up to 1,339,303 individuals. Proteins that passed both the discovery and validation Mendelian randomization analysis, sensitivity analysis, heterogeneity test, and pleiotropy test, were associated with ≥2 outcomes, and received strong support from co‐localization analysis (PP.H4.abf ≥0.80) and were classified as tier 1 proteins. Results We identified three tier 1 proteins (LRP11, ITIH1, and ADGRF5), whose genes have not been previously identified as causal genes for migraine in genetic studies. LRP11 was significantly associated with the risk of any migraine (OR [odds ratio] = 0.968, 95% CI [confidence interval] = 0.955–0.981, p = 1.27 × 10−6) and significantly/suggestively associated with three migraine subtypes. ITIH1 was significantly associated with the risk of any migraine (OR = 1.044, 95% CI = 1.024–1.065, p = 1.08 × 10−5) and migraine with visual disturbances. ADGRF5 was significantly associated with the risk of any migraine (OR = 0.964, 95% CI = 0.946–0.982, p = 8.74 × 10−5) and suggestively associated with migraine with aura. The effects of LRP11 and ADGRF5 were further replicated using cerebrospinal fluid protein data. Apart from ADGRF5, there was no evidence of potential adverse consequences when modulating the plasma levels. We also identified another four proteins (PLCG1, ARHGAP25, CHGA, and MANBA) with no potential adverse consequences when modulating the plasma levels, and their genes were not reported by previous genetic studies. Conclusions We found compelling evidence for two proteins and suggestive evidence for four proteins that could be promising targets for migraine treatment without significant adverse consequences. The corresponding genes were not reported in previous genetic studies. Future studies are needed to confirm the causal role of these proteins and explore the underlying mechanisms.

Identifying therapeutic target genes for migraine by systematic druggable genome-wide Mendelian randomization

Proteome-wide Mendelian randomization identified potential drug targets for migraine

Multi-omics Mendelian randomization integrating GWAS, eQTL and pQTL data revealed GSTM4 as a potential drug target for migraine

Identifying novel proteins for migraine by integrating proteomes from blood and CSF with genome‐wide association data

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

Irritable Bowel Syndrome and Migraine: Evidence from Mendelian Randomization Analysis in the UK Biobank

Causal relationships between migraine and microstructural white matter: a Mendelian randomization study

MTHFR polymorphism's influence on the clinical features and therapeutic effects in patients with migraine: An observational study.

Based on systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for diabetes

Causality between migraine and cardiovascular disease: a bidirectional Mendelian randomization study

Identification of Potential Drug Targets for Myopia Through Mendelian Randomization

Mendelian randomization analysis does not reveal a causal association between migraine and Meniere's disease

HMG-CoA reductase is a potential therapeutic target for migraine: a mendelian randomization study

Association between brain resting-state functional activities and migraine: a bidirectional mendelian randomization study

Migraine and white matter lesions: a mendelian randomization study

Identifying genetically-supported drug repurposing targets for non-small cell lung cancer through mendelian randomization of the druggable genome

Mendelian randomization and colocalization analysis reveal novel drug targets for myasthenia gravis

To analyze the relationship between gut microbiota, metabolites and migraine: a two-sample Mendelian randomization study

Comprehensive Druggable Genome-Wide Mendelian Randomization Reveals Therapeutic Targets for Kidney Diseases

Mendelian randomization study of lipid metabolism characteristics and migraine risk

Genetic causal relationship between immune diseases and migraine: a Mendelian randomization study